Cash, Cash Equivalents, and Short-term Investments of Arbutus Biopharma Corp from 31 Dec 2011 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD and CAD
Description
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
Summary
Arbutus Biopharma Corp quarterly Cash, Cash Equivalents, and Short-term Investments in USD history and change rate from 31 Dec 2011 to 31 Dec 2024.
  • Arbutus Biopharma Corp Cash, Cash Equivalents, and Short-term Investments for the quarter ending 31 Dec 2024 was $122,600,000, a 7.3% decline year-over-year.
Arbutus Biopharma Corp quarterly Cash, Cash Equivalents, and Short-term Investments in CAD history and change rate from 31 Dec 2011 to 31 Dec 2024.
  • Arbutus Biopharma Corp Cash, Cash Equivalents, and Short-term Investments for the quarter ending 31 Dec 2012 was CA$46,785,518, a 409% increase year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Change (%)
Cash, Cash Equivalents, and Short-term Investments, Quarterly (CAD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Change (%)

Arbutus Biopharma Corp Quarterly Cash, Cash Equivalents, and Short-term Investments (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $122,600,000 -$9,700,000 -7.3% 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q4 2023 $132,300,000 -$52,000,000 -28% 31 Dec 2023 10-K 05 Mar 2024 2023 FY
Q4 2022 $184,300,000 -$6,700,000 -3.5% 31 Dec 2022 10-K 02 Mar 2023 2022 FY
Q2 2022 $200,600,000 +$79,300,000 +65% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $221,800,000 +$89,800,000 +68% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $191,000,000 +$67,700,000 +55% 31 Dec 2021 10-K 03 Mar 2022 2021 FY
Q3 2021 $151,900,000 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $121,300,000 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $132,000,000 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q4 2020 $123,300,000 31 Dec 2020 10-K 04 Mar 2021 2020 FY
Q4 2018 $124,617,000 -$1,735,000 -1.4% 31 Dec 2018 10-K 07 Mar 2019 2018 FY
Q4 2017 $126,352,000 -$4,207,000 -3.2% 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q4 2016 $130,559,000 -$50,745,000 -28% 31 Dec 2016 10-K 16 Mar 2018 2017 FY
Q4 2015 $181,304,000 +$69,143,000 +62% 31 Dec 2015 10-K 22 Mar 2017 2016 FY
Q4 2014 $112,161,000 +$112,092,283 31 Dec 2014 10-K 09 Mar 2016 2015 FY
Q4 2013 $68,717* -$46,955,407 31 Dec 2013 10-K 13 Mar 2015 2014 FY
Q4 2012 $47,024,124 31 Dec 2012 10-K 28 Mar 2014 2013 FY

Arbutus Biopharma Corp Quarterly Cash, Cash Equivalents, and Short-term Investments (CAD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2012 CA$46,785,518 +CA$37,601,384 +409% 31 Dec 2012 20-F 27 Mar 2013 2012 FY
Q4 2011 CA$9,184,134 31 Dec 2011 20-F 27 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.